Literature DB >> 20609303

[Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis].

A Rovira1, M Tintoré, J C Alvarez-Cermeño, G Izquierdo, J M Prieto.   

Abstract

OBJECTIVE: To establish recommendations for using and interpreting magnetic resonance imaging (MRI) results in the diagnosis and follow up of multiple sclerosis (MS).
METHOD: Based on an extensive review of the literature and on their own experience, an expert group on MS produced a consensus on recommendations for using and interpreting MRI results in the diagnosis and follow up MS.
RESULTS: A brain MRI must be performed whenever possible in the initial diagnosis and assessment of patients suspected with MS. A spinal MRI study should be performed on all patients whose clinical onset shows signs of spinal cord syndrome, when the brain MRI findings are not very specific or when the brain MRI is normal in patients diagnosed clinically with MS. Cranial studies should be performed using appropriate repositioning techniques and different MR sequences, such as proton-density and T2-weighted fast spin-echo, and Fast-FLAIR. The use of contrast is mandatory whenever attempting to determine the temporal and spatial dissemination of demyelinating lesions for the initial diagnosis, or to determine inflammatory activity or lesion progression in follow up studies.
CONCLUSIONS: The use of recommendations for using and interpreting MRI results in the diagnosis and follow up MS should help to rationalise resources and optimise the clinical results arising from its practice.

Entities:  

Mesh:

Year:  2010        PMID: 20609303

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  6 in total

1.  Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.

Authors:  Adriana Carrá; Miguel Ángel Macías-Islas; Alberto Alan Gabbai; Jorge Correale; Carlos Bolaña; Eduardo Duriez Sotelo; Juan García Bonitto; Fernando Vergara-Edwards; Darwin Vizcarra-Escobar
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

2.  A comparative MRI study for white matter hyperintensities detection: 2D-FLAIR, FSE PD 2D, 3D-FLAIR and FLAIR MIP.

Authors:  Á Paniagua Bravo; J J Sánchez Hernández; L Ibáñez Sanz; I Alba de Cáceres; J L Crespo San José; B García-Castaño Gandariaga
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

3.  Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Authors:  Anthony Traboulsee; Laurent Létourneau-Guillon; Mark Steven Freedman; Paul W O'Connor; Aditya Bharatha; Santanu Chakraborty; J Marc Girard; Fabrizio Giuliani; John T Lysack; James J Marriott; Luanne M Metz; Sarah A Morrow; Jiwon Oh; Manas Sharma; Robert A Vandorpe; Talia Alexandra Vertinsky; Vikram S Wadhwa; Sarah von Riedemann; David K B Li
Journal:  Can J Neurol Sci       Date:  2015-04-21       Impact factor: 2.104

4.  Predictive value of early brain atrophy on response in patients treated with interferon β.

Authors:  Francisco Carlos Pérez-Miralles; Jaume Sastre-Garriga; Angela Vidal-Jordana; Jordi Río; Cristina Auger; Deborah Pareto; Mar Tintoré; Alex Rovira; Xavier Montalban
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-02

5.  MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?

Authors:  Christine Egger; Roland Opfer; Chenyu Wang; Timo Kepp; Maria Pia Sormani; Lothar Spies; Michael Barnett; Sven Schippling
Journal:  Neuroimage Clin       Date:  2016-11-20       Impact factor: 4.881

6.  Characterization of Enhancing MS Lesions by Dynamic Texture Parameter Analysis of Dynamic Susceptibility Perfusion Imaging.

Authors:  Rajeev K Verma; Johannes Slotboom; Cäcilia Locher; Mirjam R Heldner; Christian Weisstanner; Eugenio Abela; Frauke Kellner-Weldon; Martin Zbinden; Christian P Kamm; Roland Wiest
Journal:  Biomed Res Int       Date:  2016-01-13       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.